Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Adjuvant gemcitabine+S1 as adjuvant therapy for resectable pancreatic cancer: A real-world experience in a single-center retrospective study.
Authors
Hsin-Chen Lin
Taichung Veterans General Hospital, Taichung, Taiwan;
Hsin-Chen Lin , Yu-Hsuan Shih
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 673)
DOI
10.1200/JCO.2023.41.4_suppl.673
Abstract #
673
Poster Bd #
H17
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Chemotherapy dose density and effect on prognosis for patients with resectable pancreas cancer: A secondary analysis of SWOG S1505.
First Author: Sameer H. Patel
Poster
2022 ASCO Annual Meeting
Sequential first-line treatment with gemcitabine plus nab-paclitaxel (GA) followed by FOLFIRINOX (FFX) versus FFX alone in patients with metastatic pancreatic cancer (PC): GABRINOX-2 randomized phase 2 trial.
First Author: Fabienne Portales
Poster
2021 ASCO Annual Meeting
Total neoadjuvant FOLFIRINOX or gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2): A nationwide multicenter randomized controlled trial.
First Author: Quisette Janssen
Poster
2020 ASCO Virtual Scientific Program
Survival outcomes of patients with resectable pancreatic cancer treated with upfront surgery versus neoadjuvant chemotherapy: A retrospective tertiary care center experience.
First Author: Fang Liu